Literature DB >> 12429742

STAT5b, a Mediator of Synergism between c-Src and the Epidermal Growth Factor Receptor.

Michael T Kloth1, Kristen K Laughlin, Jacqueline S Biscardi, Julie L Boerner, Sarah J Parsons, Corinne M Silva.   

Abstract

Overexpression of the epidermal growth factor receptor (EGFR) and its association with the tyrosine kinase, c-Src, is correlated with increased cellular proliferation and tumorigenesis. Previous studies have shown that EGFR and c-Src co-overexpression and association leads to the c-Src-mediated phosphorylation of tyrosine 845 of the EGFR and that mutation of Tyr(845) ablates epidermal growth factor (EGF)-induced DNA synthesis. Here, we investigate the contribution of the signal transducers and activators of transcription (STAT5b) in the signaling pathways regulated by EGFR and c-Src overexpression in human breast tumor cell lines as well as in a mouse fibroblast model (C3H10T1/2). We demonstrate that 1) activation of STAT5b by EGF requires overexpression of the EGFR, 2) co-overexpression of c-Src alone does not result in EGF-induced activation of STAT5b but enhances that seen in EGFR-overexpressing cells, and 3) EGF-induced tyrosine phosphorylation of STAT5b requires Tyr(845) of the EGFR. Furthermore, the stable overexpression of a kinase-defective c-Src in the context of EGFR overexpression results in a decrease in the tyrosine phosphorylation of STAT5b in response to EGF and a more dramatic decrease in EGF-induced transcriptional activation of STAT5b, suggesting an integral role for c-Src in the physiological actions of STAT5b. Using a dominant negative STAT5b, we provide evidence that one such physiological action is to mediate EGF-induced DNA-synthesis. Finally, the use of site-specific tyrosine mutants demonstrates that EGF-induced phosphorylation of STAT5b involves not only tyrosine 699 of STAT5b, which is required for its transcriptional activation, but also three previously identified tyrosines in the C terminus of STAT5b (Tyr(725)/Tyr(740)/Tyr(743)).

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12429742     DOI: 10.1074/jbc.M207289200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  51 in total

1.  Src defines a new pool of EGFR substrates.

Authors:  Nicole Michael; Natalia Jura
Journal:  Nat Struct Mol Biol       Date:  2015-12       Impact factor: 15.369

2.  Epidermal growth factor receptor tyrosine phosphorylation and signaling controlled by a nuclear receptor coactivator, amplified in breast cancer 1.

Authors:  Tyler Lahusen; Mark Fereshteh; Annabell Oh; Anton Wellstein; Anna T Riegel
Journal:  Cancer Res       Date:  2007-08-01       Impact factor: 12.701

3.  Protein-tyrosine phosphatase PTPN9 negatively regulates ErbB2 and epidermal growth factor receptor signaling in breast cancer cells.

Authors:  Taichang Yuan; Yongping Wang; Zhizhuang J Zhao; Haihua Gu
Journal:  J Biol Chem       Date:  2010-03-24       Impact factor: 5.157

Review 4.  Structural systems biology and multiscale signaling models.

Authors:  Shannon E Telesco; Ravi Radhakrishnan
Journal:  Ann Biomed Eng       Date:  2012-04-27       Impact factor: 3.934

5.  Ligand-independent phosphorylation of Y869 (Y845) links mutant EGFR signaling to stat-mediated gene expression.

Authors:  Seungchan Yang; Kyungho Park; James Turkson; Carlos L Arteaga
Journal:  Exp Cell Res       Date:  2007-09-08       Impact factor: 3.905

Review 6.  Intelligent design of multifunctional lipid-coated nanoparticle platforms for cancer therapy.

Authors:  Srinivas Ramishetti; Leaf Huang
Journal:  Ther Deliv       Date:  2012-12

7.  Kinin b2 receptor mediates induction of cyclooxygenase-2 and is overexpressed in head and neck squamous cell carcinomas.

Authors:  Weiping Zhang; Neil Bhola; Shailaja Kalyankrishna; William Gooding; Jennifer Hunt; Raja Seethala; Jennifer R Grandis; Jill M Siegfried
Journal:  Mol Cancer Res       Date:  2008-12       Impact factor: 5.852

Review 8.  Novel actions of estrogen to promote proliferation: integration of cytoplasmic and nuclear pathways.

Authors:  Emily M Fox; Josefa Andrade; Margaret A Shupnik
Journal:  Steroids       Date:  2008-11-05       Impact factor: 2.668

9.  S731 in the transactivation domain modulates STAT5b activity.

Authors:  Amanda M Weaver; Corinne M Silva
Journal:  Biochem Biophys Res Commun       Date:  2007-08-28       Impact factor: 3.575

10.  The role of cooperativity with Src in oncogenic transformation mediated by non-small cell lung cancer-associated EGF receptor mutants.

Authors:  B M Chung; M Dimri; M George; A L Reddi; G Chen; V Band; H Band
Journal:  Oncogene       Date:  2009-03-23       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.